APAmalia Perna

Amalia Perna

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amalia Perna has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epigenomic profile of GBA1 in Parkinson's disease

    by Eloise Berson, Raphael Zaghroun, Matteo Santoro, Syed Bukhari, David Seong, Chi-Hung Shu, Amalia Perna, Tomin James, Kathleen S. Montine, Geidy E. Serrano, et al.


  • Open Access

    Whole genome deconvolution unveils Alzheimer’s resilient epigenetic signature

    by Eloise Berson, Anjali Sreenivas, Thanaphong Phongpreecha, Amalia Perna, Fiorella C. Grandi, Lei Xue, Neal G. Ravindra, Neelufar Payrovnaziri, Samson Mataraso, Yeasul Kim, et al.

    Assay for Transposase Accessible Chromatin by sequencing (ATAC-seq) accurately depicts the chromatin regulatory state and altered mechanisms guiding gene expression in disease. However, bulk sequencing entangles information from different cell types and obscures cellular heterogeneity. To address this, we developed Cellformer, a deep learning method that deconvolutes bulk ATAC-seq into cell type-specific expression across the whole genome. Cellformer enables cost-effective cell type-specific open chromatin profiling in large cohorts. Applied to 191 bulk samples from 3 brain regions, Cellformer identifies cell type-specific gene regulatory mechanisms involved in resilience to Alzheimer’s disease, an uncommon group of cognitively healthy individuals that harbor a high pathological load of Alzheimer’s disease. Cell type-resolved chromatin profiling unveils cell type-specific pathways and nominates potential epigenetic mediators underlying resilience that may illuminate therapeutic opportunities to limit the cognitive impact of the disease. Cellformer is freely available to facilitate future investigations using high-throughput bulk ATAC-seq data.